Literature DB >> 32898669

The clinical value of metagenomic next-generation sequencing in the microbiological diagnosis of skin and soft tissue infections.

Qingqing Wang1, Qing Miao1, Jue Pan1, Wenting Jin1, Yuyan Ma1, Yao Zhang1, Yumeng Yao1, Yi Su1, Yingnan Huang1, Bing Li1, Mengran Wang1, Na Li1, Sishi Cai1, Yu Luo1, Chunmei Zhou2, Honglong Wu3, Bijie Hu4.   

Abstract

BACKGROUND: Metagenomic next-generation sequencing (mNGS), with its comprehensiveness, is widely applied in microbiological diagnosis. Etiological diagnosis is of paramount clinical importance in patients with skin and soft tissue infections (SSTIs). However, the clinical application of mNGS in SSTIs is relatively less studied.
MATERIALS AND METHODS: From April 1, 2017 to December 31, 2019, 96 SSTI cases were collected. The positive rates of pathogens detected by mNGS and culture were compared by analyzing tissue samples, pus, swabs, and/or interstitial fluids obtained from the infected parts. Modification of the antibiotic treatment strategy due to mNGS was also assessed.
RESULTS: The sensitivity of mNGS for detecting pathogens in SSTI cases was superior to that of culture testing (67.7% vs 35.4%; p < 0.01). Significantly higher identification rates for viruses (10.4% vs 0.0%; p < 0.01) and anaerobes (11.5% vs 1.0%; p < 0.01) were obtained with mNGS compared to culture. Of note, rare pathogens such as Vibrio vulnificus and Bartonella henselae were also detected by mNGS. Importantly, the proportion of multi-pathogen SSTIs detected by mNGS was higher than that of multi-pathogen SSTIs detected by culture (16.7% vs 6.3%; p = 0.035). The rate of targeted antibiotic treatment was significantly higher in mNGS-positive cases than in mNGS-negative cases (41.7% vs 3.8%; p < 0.01). In culture-negative and mNGS-positive cases, the improvement rate was higher than that in mNGS-negative cases, but this was not statistically significant (75.0% vs 73.1%; p = 0.864).
CONCLUSIONS: mNGS is a promising tool for the etiological diagnosis of SSTIs, particularly in identifying viruses, anaerobes, and multi-pathogen infections. The application of mNGS testing in clinical practice could change antibiotic treatment strategies and partly benefit clinical outcomes.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antibiotic treatment; Diagnostic; Metagenomic next-generation sequencing; Sensitivity; Skin and soft tissue infections

Mesh:

Substances:

Year:  2020        PMID: 32898669     DOI: 10.1016/j.ijid.2020.09.007

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

1.  Profile of Bacteria with ARGs Among Real-World Samples from ICU Admission Patients with Pulmonary Infection Revealed by Metagenomic NGS.

Authors:  Huijuan Chen; Xinhua Bai; Yang Gao; Wenxuan Liu; Xuena Yao; Jing Wang
Journal:  Infect Drug Resist       Date:  2021-11-27       Impact factor: 4.003

2.  High-throughput next-generation sequencing for identifying pathogens during early-stage post-lung transplantation.

Authors:  Qiao-Yan Lian; Ao Chen; Jian-Heng Zhang; Wei-Jie Guan; Xin Xu; Bing Wei; Dan-Xia Huang; Jian-Xing He; Chun-Rong Ju
Journal:  BMC Pulm Med       Date:  2021-11-07       Impact factor: 3.317

3.  The clinical value of valve metagenomic next-generation sequencing when applied to the etiological diagnosis of infective endocarditis.

Authors:  Sishi Cai; Ye Yang; Jue Pan; Qing Miao; Wenting Jin; Yuyan Ma; Chunmei Zhou; Xiaodong Gao; Chunsheng Wang; Bijie Hu
Journal:  Ann Transl Med       Date:  2021-10

4.  Metagenomic Sequencing and Histology on a Chronic Wound Identified Epstein-Barr Virus-Associated Lymphoma.

Authors:  Wan-Ting Yang; I Chiang; Chien-Hao Tseng; Chun Cheng; Jyun-Hong Lin; Po-Yu Liu; Yao-Ting Huang
Journal:  Evol Bioinform Online       Date:  2022-07-18       Impact factor: 2.031

5.  Metagenomic next-generation sequencing may assist diagnosis of cat-scratch disease.

Authors:  Mingxia Li; Kunli Yan; Peisheng Jia; Erhu Wei; Huaili Wang
Journal:  Front Cell Infect Microbiol       Date:  2022-09-16       Impact factor: 6.073

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.